Healthcare / Pharmaceutical RetailersSaudi
$26.60
-0.48 (-1.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $43.7M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$253M
P/E
29.7x
↑EV/EBITDA
13.4x
↑ROE
6.6%
↑Gross Margin
32.9%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.4%
FCF CAGR
+10.5%
FCF margin
5.5%
FCF / Net income
2.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $454.7M · net income $8.4M · FCF $25.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $454.7M | $454.7M | $430.8M | $407.7M | $367.1M |
| Net Income | $8.4M | $8.4M | $7.9M | $11.4M | $19.1M |
| EBITDA | $18.0M | $18.0M | $16.3M | $19.5M | $25.6M |
| EPS | — | — | 0.83 | 1.20 | 2.01 |
| Gross Margin | 32.9% | 32.9% | 33.0% | 31.7% | 32.3% |
| Operating Margin | 2.4% | 2.4% | 1.8% | 3.4% | 6.6% |
| Net Margin | 1.8% | 1.8% | 1.8% | 2.8% | 5.2% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 1.23 | 5.21 | 1.04 |
| Cash Flow | |||||
| Free Cash Flow | $25.0M | $25.0M | $43.7M | $68.1M | $18.5M |
| Returns | |||||
| ROE | 6.6% | 6.6% | 5.7% | 35.1% | 16.1% |
| Valuation | |||||
| P/E | 29.68 | 29.68 | 36.14 | 25.42 | — |
| EV/EBITDA | 13.37 | 13.37 | 27.88 | 22.81 | — |
| P/B | 1.96 | 1.96 | 2.06 | 8.94 | — |
| Growth & Yield | |||||
| Revenue Growth | 5.6% | 5.6% | 5.6% | 11.1% | — |
| EPS Growth | — | — | -30.8% | -40.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.83 → n/d
Residual
-18.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.